Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Sr., Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 100.

https://doi.org/10.1182/blood-2021-144591

Published: 2021

Journal Articles

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Meagan A. Jacoby, David A. Sallman, Bart L. Scott, Megan Haney, Fei Wan, John F. DiPersio, Ramzi Abboud, Keith E. Stockerl-Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy

Blood (2021) 138 (Supplement 1): 540.

https://doi.org/10.1182/blood-2021-151137

Published: 2021

Journal Articles

Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study

Andrew M. Brunner, Yiwen Liu, Lourdes M. Mendez, Jacqueline S. Garcia, Philip C. Amrein, Donna S. Neuberg, Emma Dean, Simon Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby

Blood (2021) 138 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2021-147301

Published: 2021

Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Blood (2021) 138 (Supplement 1): 241.

https://doi.org/10.1182/blood-2021-145613

Published: 2021

Journal Articles

Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples

Michael Slade, MDMS, Michelle O'Laughlin, Robert S Fulton, Eric J. Duncavage, MD, Timothy J Ley, MD, Meagan A. Jacoby, MD, David H Spencer, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-133279

Published: 2020

Journal Articles

Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

Meagan A. Jacoby, Laura E. Finn, MD, Ashkan Emadi, MD, PhD, Nakhle S. Saba, MD, Bayard L. Powell, MD, Karen P. Seiter, MD, Rosella Garcia, Stefan Faderl, Heather J. Male

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-136880

Published: 2020

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Andrew J Menssen, BA, Ajay Khanna, Christopher A Miller, PhD, Gue Su Chang, PhD, Jin J Shao, Sridhar Nonavinkere Srivatsan, MS, Joshua Robinson, Michelle O'Laughlin, Catrina Fronick, BS, Robert Fulton, MS, Kimberly J Brendel, Sharon E Heath, Peter Westervelt, MDPhD, John F. DiPersio, MD PhD, Daniel C. Link, MD, Meagan A. Jacoby, Eric Duncavage, MD, Timothy J Ley, MD, Matthew J. Walter, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-140394

Published: 2020

Journal Articles

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

Blood (2017) 129 (10): 1397–1401.

https://doi.org/10.1182/blood-2016-10-745273

Published: 2017

Includes: Supplemental data

Journal Articles

Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis

Kilannin Krysiak, PhD, Meagan A. Jacoby, MD PhD, Zachary L. Skidmore, MS, Arpad M. Danos, PhD, Michelle O'Laughlin, BS, Eric J. Duncavage, MD, Matthew J. Walter, MD, Malachi Griffith, PhD, Obi L. Griffith, PhD, Lukas D. Wartman, MD

Blood (2016) 128 (22): 4306.

https://doi.org/10.1182/blood.V128.22.4306.4306

Published: 2016

Journal Articles

Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

Meagan A. Jacoby, MD PhD, Eric J. Duncavage, MD, Gue Su Chang, PhD, Christopher A. Miller, PhD, Jin Shao, Kevin Elliott, Robert S. Fulton, PhD, Catrina Fronick, Michelle O'Laughlin, Daniel C. Link, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Timothy J. Ley, MD, Timothy A. Graubert, MD, Matthew J. Walter, MD, Richard K Wilson, PhD

Blood (2016) 128 (22): 5506.

https://doi.org/10.1182/blood.V128.22.5506.5506

Published: 2016

Journal Articles

Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression

Eric J. Duncavage, MD, Meagan A. Jacoby, MD PhD, Chris Miller, PhD, Gue Su Chang, PhD, Jin Shao, Kevin Elliot, Catrina Fronick, Michelle O'Laughlin, Robert Fulton, PhD, Richard K Wilson, PhD, Timothy A. Graubert, MD, Matthew J. Walter, MD

Blood (2016) 128 (22): 959.

https://doi.org/10.1182/blood.V128.22.959.959

Published: 2016

Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Blood (2015) 126 (23): 258.

https://doi.org/10.1182/blood.V126.23.258.258

Published: 2015

Journal Articles

A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome

Meagan A. Jacoby, MD PhD, Camille N. Abboud, MD FACP, John F Dipersio, MD PhD, Amanda F. Cashen, MD, Matthew J. Walter, MD, Rigoberto De Jesus Pizarro, Geoffrey L. Uy, MD

Blood (2015) 126 (23): 1686.

https://doi.org/10.1182/blood.V126.23.1686.1686

Published: 2015

Journal Articles

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

Blood (2015) 126 (23): 610.

https://doi.org/10.1182/blood.V126.23.610.610

Published: 2015

Journal Articles

Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

Brian T Hess, MD, Feng Gao, PhD, John F. DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, MD, Geoffrey L. Uy, MD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD FACP, Mark A. Schroeder, MD, Iskra Pusic, MD, Armin Ghobadi, MD, Amanda F. Cashen, MD, Todd A Fehniger, MD PhD, Meagan A. Jacoby, MD PhD, Rizwan Romee, MD

Blood (2015) 126 (23): 1950.

https://doi.org/10.1182/blood.V126.23.1950.1950

Published: 2015

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples

Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis

Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

A Phase I Study of Vosaroxin Plus Azacitidine for Patients with Myelodysplastic Syndrome

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only